- Details
- (Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...
|
- Details
- (Length of Discussion: 30 min) Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical applica...
|
- Details
- (Lenght of Discussion: 14 min) Tom Keane reviews three key presentations from the most recent American Urological Association (AUA) 2018 meeting. Among the presentations Keane discusses is a prostate cancer Imaging presentation by the Chief of MRI and Nuclear Medicine at the San Francisco VA Medical Center, Thomas Hope, MD. During his presentation, Prostate Cancer: What PET to GET? Hope discussed...
|
- Details
- (Length of Discussion: 16 min) Dr. Tom Keane discusses the rapidly changing landscape in advanced bladder cancer with the introduction of immune checkpoint inhibitors. To begin his discussion he references a presentation by Thomas Powles, MD from the 2018 ASCO GU meeting where Dr. Powles provided an overview of immune checkpoint inhibitors in urothelial carcinoma at the current time and Dr. Powles...
|
- Details
- (Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...
|
- Details
- (Length of Discussion: 5 min) Dr. Thomas Keane discusses a group analysis of an online tool to explore evolving practice patterns among patients with renal cell carcinoma (RCC), a topic presented by Dr. Won Kim from UCSF. The complex and rapidly evolving treatment landscape for advanced RCC poses challenges for healthcare providers, particularly those in community settings, to make treatment decis...
|
- Details
- (Length of Discussion: 5 min) Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma. A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting. In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1...
|
- Details
- (Length of Discussion: 4 min) Dr. Thomas Keane reviews the Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial for Advanced Renal Carcinoma presentation by Dr. Daniel George at the ASCO GU 2018 meeting. Cabozantinib, a small molecule designed to target the MET and ALK pathways in addition to VEGFR2 pathway has been shown to be superior t...
|
- Details
- (Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...
|
- Details
- (Length of Discussion 17 min) Dr. Thomas Keane reviews recent groundbreaking data presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium focusing on the much awaiting results of the SPARTAN trial. Dr. Keane started by highlighting the SPARTAN Trial presentation by Dr. Eric Small. A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-r...
|
